Precigen (PGEN) Income from Non-Controlling Interests (2012 - 2019)
Precigen's (PGEN) quarterly Income from Non-Controlling Interests came in at -$165000.0 in Q2 2019, up 88.6% year-on-year from -$87488.1 in Q2 2018, and up 88.44% on a QoQ basis from -$1.4 million in Q1 2019.
Precigen (PGEN) Income from Non-Controlling Interests (2012 - 2019) Analysis & Trends
Precigen (PGEN) has 8 years of Income from Non-Controlling Interests data on file, last reported at -$165000.0 in Q2 2019.
- On a quarterly basis, Income from Non-Controlling Interests rose 88.6% year-over-year to -$165000.0 in Q2 2019; TTM through Mar 2020 was -$165000.0, a 97.03% increase from a year earlier, with the FY2019 full-year figure at -$1.6 million, up 70.35% from the prior year.
- Income from Non-Controlling Interests for Q2 2019 stood at -$165000.0, up from -$1.4 million in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for PGEN reached as high as -$165000.0 in Q2 2019 and fell as low as -$6.7 million in Q4 2017.
- Historically, Income from Non-Controlling Interests has averaged -$1.3 million across 5 years, with a median of -$1.0 million in 2016.
- Across the five-year window, Income from Non-Controlling Interests slumped 761.81% in 2017 and surged 88.6% in 2019, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at -$561000.0 in 2015, then sank by 38.15% to -$775000.0 in 2016, then plunged by 761.81% to -$6.7 million in 2017, then surged by 81.18% to -$1.3 million in 2018, then soared by 86.87% to -$165000.0 in 2019.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$165000.0 in Q2 2019, -$1.4 million in Q1 2019, and -$1.3 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.97 Bn | 466.18 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.05 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.42 Bn | 959.66 Mn | - |
| 10 | Precigen | 1.97 Bn | 1.97 Bn | 20.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | -165,000.00 |
| Mar 31, 2019 | -1.43 Mn |
| Dec 31, 2018 | -1.26 Mn |
| Sep 30, 2018 | -1.42 Mn |
| Jun 30, 2018 | -1.45 Mn |
| Mar 31, 2018 | -1.24 Mn |
| Dec 31, 2017 | -6.68 Mn |
| Sep 30, 2017 | -1.15 Mn |
| Jun 30, 2017 | -998,000.00 |
| Mar 31, 2017 | -978,000.00 |
| Dec 31, 2016 | -775,000.00 |
| Sep 30, 2016 | -1.03 Mn |
| Jun 30, 2016 | -967,000.00 |
| Mar 31, 2016 | -891,000.00 |
| Dec 31, 2015 | -561,000.00 |
| Sep 30, 2015 | -816,000.00 |
| Jun 30, 2015 | -831,000.00 |
| Mar 31, 2015 | -1.29 Mn |
| Dec 31, 2014 | -899,000.00 |
| Sep 30, 2014 | -1.14 Mn |